-->

Elanco closes acquisition of Bayer Animal Health

The transaction is valued at $6.89 billion and expands Elanco’s scale and capabilities, taking on Bayer’s focus in retail and online to better serve veterinarians and pet owners.

GREENFIELD, Ind. (BUSINESS WIRE) – Elanco Animal Health Incorporated announced today it has closed the acquisition of Bayer Animal Health.

The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry.

“Nearly two years into our journey as an independent company, we have made significant progress in creating a purpose-driven, independent global company dedicated to animal health – all while weathering the century’s most significant animal and human health pandemics: African Swine Fever and COVID-19,” Jeff Simmons, president and CEO of Elanco, said.

“Delivering on the timely close of the acquisition and bringing momentum into Day 1 in this challenging environment underscores the deep capability and disciplined execution from both companies,” Simmons said.

The pandemic has accelerated key trends transforming the industry, particularly pet owners’ desire to access veterinary care and animal health products in a variety of forms, from curbside care and telemedicine to online purchases shipped direct to the doorstep.

The combination of Elanco and Bayer Animal Health joins Elanco’s existing strong relationship with the veterinarian with Bayer Animal Health’s focus in retail and online in order to create an omni-channel leader best positioned to serve veterinarians and pet owners where they want to shop.